Navigation Links
Lexicon Announces Commencement of Rights Offering to Stockholders
Date:11/22/2011

umatoid arthritis, all of which were discovered by Lexicon's research team.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's expectations regarding the completion, timing and size of the rights offering.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Words such as "anticipated," "will," "proposed" and similar expressions are intended to identify these forward-looking statements.  There are a number of important factors that could cause Lexicon's results to differ materially from those indicated by these forward-looking statements, including risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the rights offering.  There can be no assurance that Lexicon will be able to complete the rights offering on the anticipated terms, or at all.  Additional risks and uncertainties relating to the rights offering, Lexicon and its business can be found under the headings "Factors Affecting Forward Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission, in Lexicon's other filings with the Securities and Exchange Commission and under the heading "Risk Factors" in the final prospectus supplement relating to the rights offering to be filed with the Securities and Exchange Commission.  Unless required by applicable law, Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
4. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
5. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
6. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
7. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
8. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
9. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
11. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Sept. 1, 2014 ... is available in its catalogue: Antibody ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... new class of therapeutic agents, gaining increasing attention ... addressed as the marriage of an antibody with ...
(Date:8/30/2014)... --  Royal Philips  (NYSE: PHG, AEX: PHIA) today announced ... system designed to enable global hospitals and health systems ... cost pressures. Making its debut at the  European Society ... this week, Affiniti provides innovative technology to ... deliver high quality patient care. "Affiniti ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
(Date:9/2/2014)... 2 September 2014: Health structures explain nearly 20% ... to the results of a joint ESC-OECD study ... Maggioni. Clinical variables explained more than 80% of ... unique evaluation which combines clinical data and health ... fuller picture of the reasons some patients with ...
(Date:9/2/2014)... Developers and plugin specialist of Final Cut ... from Pixel Film Studios. , “ProIntro has enabled users ... Christina Austin, CEO of Pixel Film Studios. “Blurring the ... game changer.” , Learn how to create a title ... Studios. ProIntro is a package of professionally designed titles ...
(Date:9/2/2014)... NOVAtime Technology, Inc. ( http://www.novatime.com ... announced today that Avon Health Center, a long-time ... NOVAtime 4000 Time and Attendance / Workforce ... latest smart clock, the NT7000 . , Avon ... is an award-winning nursing facility that provides short-term ...
(Date:9/2/2014)... “Harmonicas have been formally used ... to help people with COPD or asthma. At ... systems,” says Dana Keller, PhD, co-inventor of the ... are much the same – improved health with ... harmonica.” , The three approaches to harmonicas in ...
(Date:9/2/2014)... September 02, 2014 September 2014 – The ... gone. But even though men shave daily – and commit ... rough and irritated skin isn’t inevitable, according to Joshua ... , For decades, skin care was something in which ... surge in men of all ages who realize that their ...
Breaking Medicine News(10 mins):Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 3
... dengue fever in early stage was launched in India Monday ... distributor of life science research products and clinical diagnostics. ... to diagnose dengue on the first day of symptoms, the ... - the first in the Indian market - is based ...
... to be safer to use than laser surgery to correct ... being contested by a physician William Mathers, M.D from Health ... comparing data from many recent studies who feels the results ... ,Dr Mathers, Professor of Ophthalmology in the OHSU School ...
... have quit the NHS rather than sign new contracts. Around ... around one million patients without an NHS dentist. ... over the changes. If their issues are still not resolved, ... switch to private practice. ,Since the introduction of ...
... term schizophrenia should be done away with, as it has ... is a harmful concept," said Professor Marius Romme, a visiting ... in Birmingham.,He added, "Symptoms such as delusions, hearing voices and ... be reactions to traumatic and troubling events in life. " ...
... medicine regulators to begin selling its new breast cancer pill ... last month, and comes slightly earlier than some commentators were ... GSK's most promising pipeline drugs as well as a potential ... the drug could cross 2 bln used by 2010. ...
... patients before the surgical removal of the tumour, than ... 1 %. The usual treatment for bowel cancer ... and once reappeared, treatment is difficult and usually incurable. ... to compare the effect of radiotherapy before and after ...
Cached Medicine News:Health News:Laser Surgery Safer Than Contact Lenses? 2Health News:NHS Dentists Shortage worsens over New Contracts 2Health News:‘Schizophrenia’ term ought to be abolish 2
Mid-level interpretive resting ECG...
... The ECG-9010 meets IEC60601-2-51 new ... accuracy and digital filter performance. ECG ... on a Windows PC with the ... be changed for operating in other ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... Critical Care Xpress is an innovative, stat ... and hematology with on-board co-oximetry and integrated ... instrument. Measured tests include pH, PCO 2 ... hematocrit and hemoglobin, sodium, potassium, chloride, ionized ...
Medicine Products: